| Dr Joshua K Fine, MD | |
|
3417 Gaston Ave, Suite 830, Dallas, TX 75246-0830 | |
| (214) 826-6235 | |
| (214) 828-4633 |
| Full Name | Dr Joshua K Fine |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 36 Years |
| Location | 3417 Gaston Ave, Dallas, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447245683 | NPI | - | NPPES |
| 114605204 | Medicaid | TX | |
| P00300421 | Other | TX | RR MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | H6218 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baylor University Medical Center | Dallas, TX | Hospital |
| Baylor Scott & White Heart & Vascular Hospital - Dallas | Dallas, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Urology Clinics Of North Texas, Pllc | 5496736415 | 68 |
News Archive
"Pre-positioning food stocks has some important advantages besides saving time: it can lower program costs for the food itself and shipping. Mostly, however, it's crazy that the Congress still requires that U.S. food aid be bought here and transported around the world on U.S.-flagged ships," Kimberly Ann Elliott, a senior fellow at the Center for Global Development, writes on the "Views from the Center" blog.
NaturalNano, Inc. announced that Andrew Hughes is presenting today research from Cornell University's Department of Biomedical Engineering that reports significant improvement in the ability of medical devices in development to target the separation of circulating tumor cells (CTCs) from blood are significantly improved by the use of NaturalNano's Halloysite Nanotubes (HNT) as part of the surface. The devices are designed to remove CTCs from the blood of cancer patients as part of a more personalized approach to cancer treatment.
Women sexually abused in childhood and adolescence who suffer from depression and post-traumatic stress disorder benefit significantly from Interpersonal Psychotherapy-Trauma, according to a Rutgers researcher.
Pfizer Oncology will present data from across its portfolio, including results from long-term follow-up of Aromasin® (exemestane tablets) in a study of early breast cancer, updated study results from a Phase 3 study of Sutent® (sunitinib malate) in pancreatic neuroendocrine tumors (NET), and early-stage research of investigational agents PF-02341066 and figitumumab (CP-751,871) in patients with non-small cell lung cancer (NSCLC).
› Verified 6 days ago
| Entity Name | Urology Clinics Of North Texas, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780971549 PECOS PAC ID: 5496736415 Enrollment ID: O20040526000711 |
News Archive
"Pre-positioning food stocks has some important advantages besides saving time: it can lower program costs for the food itself and shipping. Mostly, however, it's crazy that the Congress still requires that U.S. food aid be bought here and transported around the world on U.S.-flagged ships," Kimberly Ann Elliott, a senior fellow at the Center for Global Development, writes on the "Views from the Center" blog.
NaturalNano, Inc. announced that Andrew Hughes is presenting today research from Cornell University's Department of Biomedical Engineering that reports significant improvement in the ability of medical devices in development to target the separation of circulating tumor cells (CTCs) from blood are significantly improved by the use of NaturalNano's Halloysite Nanotubes (HNT) as part of the surface. The devices are designed to remove CTCs from the blood of cancer patients as part of a more personalized approach to cancer treatment.
Women sexually abused in childhood and adolescence who suffer from depression and post-traumatic stress disorder benefit significantly from Interpersonal Psychotherapy-Trauma, according to a Rutgers researcher.
Pfizer Oncology will present data from across its portfolio, including results from long-term follow-up of Aromasin® (exemestane tablets) in a study of early breast cancer, updated study results from a Phase 3 study of Sutent® (sunitinib malate) in pancreatic neuroendocrine tumors (NET), and early-stage research of investigational agents PF-02341066 and figitumumab (CP-751,871) in patients with non-small cell lung cancer (NSCLC).
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Joshua K Fine, MD 3600 Gaston Ave, Suite 1205, Dallas, TX 75246-1800 Ph: (214) 826-6235 | Dr Joshua K Fine, MD 3417 Gaston Ave, Suite 830, Dallas, TX 75246-0830 Ph: (214) 826-6235 |
News Archive
"Pre-positioning food stocks has some important advantages besides saving time: it can lower program costs for the food itself and shipping. Mostly, however, it's crazy that the Congress still requires that U.S. food aid be bought here and transported around the world on U.S.-flagged ships," Kimberly Ann Elliott, a senior fellow at the Center for Global Development, writes on the "Views from the Center" blog.
NaturalNano, Inc. announced that Andrew Hughes is presenting today research from Cornell University's Department of Biomedical Engineering that reports significant improvement in the ability of medical devices in development to target the separation of circulating tumor cells (CTCs) from blood are significantly improved by the use of NaturalNano's Halloysite Nanotubes (HNT) as part of the surface. The devices are designed to remove CTCs from the blood of cancer patients as part of a more personalized approach to cancer treatment.
Women sexually abused in childhood and adolescence who suffer from depression and post-traumatic stress disorder benefit significantly from Interpersonal Psychotherapy-Trauma, according to a Rutgers researcher.
Pfizer Oncology will present data from across its portfolio, including results from long-term follow-up of Aromasin® (exemestane tablets) in a study of early breast cancer, updated study results from a Phase 3 study of Sutent® (sunitinib malate) in pancreatic neuroendocrine tumors (NET), and early-stage research of investigational agents PF-02341066 and figitumumab (CP-751,871) in patients with non-small cell lung cancer (NSCLC).
› Verified 6 days ago
Dr. Xiaosong Meng, M.D., PH.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 5200 Harry Hines Blvd, Dallas, TX 75235 Phone: 214-590-8000 | |
Bruce Jeremy Schlomer, MD Urology Medicare: Medicare Enrolled Practice Location: 2350 N Stemmons Fwy, Suite D-4300, Mc F4.04, Dallas, TX 75207 Phone: 214-456-2444 | |
Dr. Jodi Antonelli, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-648-5615 Fax: 214-648-8786 | |
Dr. Eric Bryan Smith, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 3417 Gaston Ave, Ste 830, Dallas, TX 75246 Phone: 214-826-6235 Fax: 214-828-4633 | |
Gary Evan Lemack, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-645-8765 | |
Dr. Homa Jackson Porter Ii, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 8230 Walnut Hill Ln, Suite 700, Dallas, TX 75231 Phone: 214-691-1902 Fax: 214-987-1845 | |
Dr. Michelle Leigh Mcdonald, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 6201 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-633-5555 |